Abstract:Prostate cancer is an exemplar of an enhancer-binding transcription factor-driven disease. The androgen receptor (AR) enhanceosome complex comprised of chromatin and epigenetic coregulators assembles at enhancer elements to drive disease progression. The paralog lysine acetyltransferases p300 and CBP deposit histone marks that are associated with enhancer activation. Here, we demonstrate that p300/CBP are determinant cofactors of the active AR enhanceosome in prostate cancer. Histone H2B N-terminus multisite lysine acetylation (H2BNTac), which is exclusively reliant on p300/CBP catalytic function, marked active enhancers and was notably elevated in prostate cancer lesions relative to the adjacent benign epithelia. Degradation of p300/CBP rapidly depleted acetylation marks associated with the active AR enhanceosome, which was only partially phenocopied by inhibition of their reader bromodomains. Notably, H2BNTac was effectively abrogated only upon p300/CBP degradation, which led to a stronger suppression of p300/CBP-dependent oncogenic gene programs relative to bromodomain inhibition or the inhibition of its catalytic domain. In vivo experiments using an orally active p300/CBP proteolysis targeting chimera (PROTAC) degrader (CBPD-409) showed that p300/CBP degradation potently inhibited tumor growth in preclinical models of castration-resistant prostate cancer and synergized with AR antagonists. While mouse p300/CBP orthologs were effectively degraded in host tissues, prolonged treatment with the PROTAC degrader was well tolerated with no significant signs of toxicity. Taken together, our study highlights the pivotal role of p300/CBP in maintaining the active AR enhanceosome and demonstrates how target degradation may have functionally distinct effects relative to target inhibition, thus supporting the development of p300/CBP degraders for the treatment of advanced prostate cancer.

Coactivating Factors P300 and CBP Are Transcriptionally Crossregulated by Egr1 in Prostate Cells, Leading to Divergent Responses

Co-factors p300 and CBP catch Egr1 in their network.

Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells.

Distinct Roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in Nuclear Receptor Transactivation.

E2F1 Renders Prostate Cancer Cell Resistant to ICAM-1 Mediated Antitumor Immunity by NF-κB Modulation.

E2f1 Induces Tumor Cell Survival Via Nuclear Factor-Kappa B-Dependent Induction of Egr1 Transcription in Prostate Cancer Cells

p300-Dependent ATF5 acetylation is essential for Egr-1 gene activation and cell proliferation and survival

EGR1 Promotes Proliferation in Prostatic Hyperplasia Epithelial BPH-1 Cells

Positive and Negative Modulation of the Transcriptional Activity of the ETS Factor ESE-1 through Interaction with p300, CREB-binding Protein, and Ku 70/86

Up-Regulation Of P300 Binding And P50 Acetylation In Tumor Necrosis Factor-Alpha-Induced Cyclooxygenase-2 Promoter Activation

Up-regulation of p300 Binding and p50 Acetylation in Tumor Necrosis Factor-α-induced Cyclooxygenase-2 Promoter Activation

The transcriptional coactivator CBP/p300 is an evolutionarily conserved node that promotes longevity in response to mitochondrial stress

Differential contribution of p300 and CBP to regulatory element acetylation in mESCs

p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer

p300/CBP and p300/CBP-associated Factor with Transcriptional Regulation

Structure and Functions of Transcriptional Coactivators P300／cbp and Their Roles in Regulation of Interleukin Gene Expression

Suppression of growth and transformation and induction of apoptosis by EGR-1.

p300 regulates the synergy of steroidogenic factor-1 and early growth response-1 in activating luteinizing hormone-beta subunit gene.

A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors.

P300/cyclic adenosine monophosphate response element binding protein and its biological functions

Combinatorial transcription factor regulation of the cyclic AMP-response element on the Pgc-1alpha promoter in white 3T3-L1 and brown HIB-1B preadipocytes